Paying For Gene Therapy: Will Pharma Be First In Line?
With 15 new gene and cell-based therapies in late-stage testing, the time is now to consider a critical strategic question: is there a pricing model for these budget-busting treatments that works in both safeguarding returns to innovators and providing access to patients at a price society is willing to pay? An analysis by ZS Associates looks at the options for biopharma going forward.
You may also be interested in...
Otherwise, CMS proposes pegging inpatient hospital reimbursement for CAR-T treatment to bundled rate for bone marrow transplants and potentially providing add-on payments for at least a couple of years.